Abstract
Background and aims: Oxidative stress and inflammation are postulated to be involved in the pathogenesis of the age-related macular degeneration (AMD) although the mechanism linking the oxidation and inflammation is still unknown. The aim of this study was the analysis of the antioxidant capacity measured by levels of the antioxidant enzymes: superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) and total antioxidant status (TAS) along with the inflammatory markers such as Creactive protein (CRP), interleukin-6 (IL-6) and fibrinogen in AMD patients in order to analyze the relationship of the inflammatory markers with the antioxidant parameters and their association with AMD. Methods: The cross-sectional study, carried out in the University clinical setting, included 84 patients with the age-related macular degeneration, aged 71.25±7.14 years and 84 aged-matched control subjects (CG). Results: Statistical analysis revealed significantly lower GR (p=0.007) and TAS (p<0.000) values in the group of AMD patients compared to the controls. Logistic regression analysis showed that higher values of inflammatory markers (CRP>3 mg/L, IL>4.9 pg/mL, fibrinogen>3.8 g/L) and lower values of antioxidative parameters (SOD<900 U/gHb, GR<55 U/L and TAS<1.15 mmol/L) were significantly associated with AMD (ORCRP: 1.29, 95% CI 0.54-3.12, p<0.05; ORIL-6: 3.53, 95% CI 1.16–10.75, p=0.024; ORFIB: 3.06, 95% CI 1.78–7.92, p=0.019; ORSOD: 2.39, 95% CI 0.78–7.35, p<0.05; ORGR: 4.04, 95% CI 1.28–12.73, p=0.013; ORTAS: 2.9, 95% CI 1.4–6.3, p=0.032). Conclusions: Based on the results obtained, it may be concluded that the antioxidant defense system was significantly reduced in patients with AMD and the probability to develop AMD was higher in older individuals with lower values of antioxidant parameters and higher values of inflammatory markers.
Similar content being viewed by others
References
Colak E. New markers of oxidative modifications to macromolecules. J Med Biochem 2008; 27: 1–16.
Coleman H, Chan CC, Ferris FL, Chew EY. Age-related macular degeneration. Lancet 2008; 372: 1835–45.
Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58: 353–63.
Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Molecular Vision 1999; 5: 32–45.
Lange CAK, Bainbridge JWB. Oxygen sensing in retinal health and disease. Ophthalmologica 2012; 227: 115–31.
Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of the aging. Proc Natl Acad Sci USA 1993; 90: 7915–22.
Nikolic-Kokic A, Blagojevic D, Spasic MB. Complexity of free radical metabolism in human erythrocytes. J Med Biochem 2010; 29: 189–95.
Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 2005; 112: 2076–80.
Schaumberg DA, Christen WG, Buring JE, Glynn RJ, Rifai N, Ridker PM. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol 2007; 125: 300–5.
Omoigui S. The interleukin-6 inflammation pathway from cholesterol to aging — Role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing 2007; 4: 1–28.
Seddon JM, George S, Rosner B, Rifai N. Progression of the agerelated macular degeneration: prospective assessment of C-reactive protein, interleukin 6 and other cardiovascular biomarkers. Arch Ophthalmol 2005; 123: 774–82.
Goldstein S, Michel C, Boors A, Saran M, Czapsky G. A critical re-evaluation of some assay methods for superoxide dismutase activity. Free Radical Biol Med 1988; 4: 295–303.
Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of glutathione peroxidase. J Lab Clin Med 1967; 70: 158–63.
Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407–12.
Goldberg DM, Spooner RJ. In Bergmeyer HU (Ed) Methods of enzymatic analysis, 3rd ed. New York: Academic Press; Vol 3, 1974: pp 258–65.
Wakamatsu TH, Dogru M, Tsubota K. Tearful relations: oxidative stress, inflammation and eye diseases. Arq Bras Oftalmol 2008; 71 (Suppl):72–9.
Yildirim Z, Uegun NI, Yildirim F. The role of oxidative stress and antioxidants in pathogenesis of age-related macular degeneration. Clinics 2011; 66: 743–6.
Imamura Y, Noda S, Hashizuma K et al. Drusen, choroidal neovascularization and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci USA 2006; 103: 11282–7.
Hübner-Wozniak E, Okecka-Szymanska J, Stupnicki R, Malara M, Kozdron E. Age-related blood antioxidant capacity in men and women. J Med Biochem 2011; 30: 103–8.
Klouche M, Rose-John S, Schmiedt W, Bhakdi S. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000; 101: 1799–805.
Williams N, Bertoncello I, Jackson H, Arnold J, Kavnoudias H. The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production. Ciba Found Symp 1992; 167: 160–70.
Seino Y, Ikeda U, Ikeda M et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994; 6: 87–91.
Burstein SA. Effects of interleukin 6 on megakaryocytes and on canine platelet function. Stem Cells 1994; 12: 386–93.
Verma S, Badiwala MV, Weisel RD et al. C-reactive protein upregulates the NF-?B signaling pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003; 126: 1886–91.
Colak E, Kosanovic-Jakovic N, <Zoric L, Radosavljevic A, Stankovic S, Majkic-Singh N. The association of lipoprotein parameters and C-reactive protein in patients with age-related macular degeneration. Ophthalmic Res 2011; 46: 125–32.
Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004; 291: 704–10.
Nagaoka T, Kuo L, Ren Y, Yoshida A, Hein TW. C-Reactive Protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production. Invest Ophthalmol Vis Sci 2008; 49: 2053–60.
De Jong PT, Boekhoorn SS, Vingerling JR, Witteman JCM, Hofman A. C-reactive protein and incident aging macular disease (AMD): The Rotterdam Study. Invest Ophthalmol Vis Sci 2005; 46: E-Abstract 2379.
Kikuchi M, Nakamura M, Ishikawa K et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmol 2007; 114: 1722–7.
Boekhoom SS, Vingerling JR, Witteman JC, Hofman A, de Jong P. C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol 2007; 125: 1396–401.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Čolak, E., Majkić-Singh, N., Žorić, L. et al. The impact of inflammation to the antioxidant defense parameters in AMD patients. Aging Clin Exp Res 24, 588–594 (2012). https://doi.org/10.3275/8593
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/8593